TIL
Instil Bio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
instil bio is a cell therapy company developing tumor infiltrating lymphocytes (til) for the treatment of solid tumor cancers. til are a patient’s own t cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. the company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered til. the company is led by world-class cell therapy experts and backed by premier global institutional investors. instil is located in the greater los angeles area with additional manufacturing and research facilities in manchester, uk.
Market Cap: 1.58 Billion
Primary Exchange: NASDAQ
Website: instilbio.com
Shares Outstanding: 130 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.6797287166826859
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 908 trading days
From: 2015-05-27 To: 2023-12-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|